Comparative Analysis of Viperidae Venoms Antibacterial Profile: a Short Communication for Proteomics by Ferreira, Bruno L. et al.
Hindawi Publishing Corporation
Evidence-Based Complementaryand Alternative Medicine
Volume 2011, Article ID 960267, 4 pages
doi:10.1093/ecam/nen052
Original Article
ComparativeAnalysis of Viperidae VenomsAntibacterialProﬁle:
aShort CommunicationforProteomics
Bruno L. Ferreira,1,2 Dilvani O. Santos,1,2 Andr´ eLuisdosSantos,1,2 CarlosR.Rodrigues,2,3
C´ ıceroC.deFreitas,1 L´ ucioM. Cabral,3 and Helena C.Castro1,2
1Departamento de Biologia Celular e Molecular, Laborat´ orio de Antibi´ oticos, Bioqu´ ımica e Modelagem Molecular (LABioMol),
Instituto de Biologia, CEG, Universidade Federal Fluminense, CEP 24001–970, Niter´ oi, Brazil
2Cursos de P´ os-graduac ¸˜ ao em Neuroimunologia - IB, e Patologia - HUAP, Universidade Federal Fluminense, CEP 24001-970,
Niter´ oi, RJ, Brazil
3Laborat´ orio de Modelagem Molecular e QSAR (ModMolQSAR), Faculdade de Farm´ acia, Universidade Federal do Rio de Janeiro,
CEP 21941-590, Rio de Janeiro, RJ, Brazil
Correspondence should be addressed to Helena C. Castro, hcastrorangel@vm.uﬀ.br
Received 2 May 2007; Accepted 16 July 2008
Copyright © 2011 Bruno L. Ferreira et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Bacterial infections involving multidrug-resistant strains are one of the ten leading causes of death and an important health
problem in need for new antibacterial sources and agents. Herein, we tested and compared four snake venoms (Agkistrodon
rhodostoma, Bothrops jararaca, B. atrox and Lachesis muta) against 10 Gram-positive and Gram-negative drug-resistant clinical
bacteria strains to identify them as new sources of potential antibacterial molecules. Our data revealed that, as eﬃcient as some
antibioticscurrentlyonthemarket(minimalinhibitoryconcentration(MIC)=1–32µgmL −1),A.rhodostomaandB.atrox venoms
were active against Staphylococcus epidermidis and Enterococcus faecalis (MIC = 4.5 µgm L −1), while B. jararaca inhibited S. aureus
growth (MIC = 13 µgm l −1). As genomic and proteomic technologies are improving and developing rapidly, our results suggested
that A. rhodostoma, B. atrox and B. jararaca venoms and glands are feasible sources for searching antimicrobial prototypes for
future design new antibiotics against drug-resistant clinical bacteria. They also point to an additional perspective to fully identify
the pharmacologicalpotential of these venoms by using diﬀerent techniques.
1.Introduction
Bacterial infections are among the 10 leading causes of death
worldwide according to the World Health Organization [1,
2].The presenceand currentemergenceofthekeptmultiple-
resistant strains make the risk of these infections become
more threatening as the treatment becomes unreachable. In
fact, bacterial resistance has been the major factor responsi-
ble for increasing morbidity, mortality and health care costs
of bacterial infections [1–5]. Therefore, new antimicrobials
or antibacterial prototypes are continuously necessary for
drug design and development for treatment of infections
involving multidrug-resistant microorganisms [1, 2, 6, 7].
Snake venoms are a complex mixture of proteins and
peptides that display potential biological activities and may
lead to the production of new drugs of potential therapeutic
value [8, 9]. A good example is the bradykinin-potentiating
peptides (BPPs), which are naturally occurring inhibitors of
the somatic angiotensin-converting enzyme (ACE) found in
Bothrops jararaca venom [10]. The chemical and pharma-
cological properties of these peptides were essential for the
development of captopril, the ﬁrst active site directed
inhibitor of ACE, currently used to treat human hyperten-
sion [11].
Lately, several naturally occurring peptides presenting
antimicrobial activity have been described in the literature.
However, Viperidae snake venoms that are an enormous
source of peptides have not been fully explored for searching
such biological activity [5, 12]. Therefore, in this study,
we tested the antibiotic proﬁle of four snake venoms
from three diﬀerent genera of Viperidae family (Agkistrodon
rhodostoma, Bothrops atrox, B. jararaca and Lachesis muta)2 Evidence-Based Complementary and Alternative Medicine
against 10 drug-resistant Gram-positive and Gram-negative
bacteria clinical strains. Based on captopril history, our
purpose is to identify some of these venoms as potential
source for ﬁnding new and eﬀective antibacterial prototypes.
2.Materialsand Methods
2.1. Materials. Each venom was purchased from Sigma (St
Louis, MO, USA) and one L. muta venom sample was also
obtained from each Brazilian governmental sources—
Butantan Institute, SP, Ezequiel Dias Institute, SP and Vital
Brazil Institute, RJ, Brazil. The 10 Gram-positive (Ente-
rococcus faecalis, Staphylococcus epidermidis and S. aureus)
and Gram-negative (Escherichia coli, Serratia marcenses, Pro-
teus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae,
Acinetobacter calcoaceticus and Klebsiella pneumoniae)d r u g -
resistant clinical bacteria were isolated from patients of the
Hospital Antˆ onioPedrofromFluminenseFederalUniversity.
All other reagents were from Sigma. After isolation, the
bacterial strains were kept frozen in 10% milk-sterilized
solution containing 10% glycerin.
2.2. Methods
2.2.1. Sensibility Test. The test and MIC were performed
according to the National Committee for Clinical Labo-
ratory Standards (NCCLS), in M¨ ueller-Hinton medium as
described elsewhere [13]. Brieﬂy, the strains were grown
at 37◦Ci nM ¨ ueller-Hinton medium. Then, 1µLo ft h e
snake venom solutions prepared with sterilized distilled and
deionized water (20mgmL−1) was placed in Whatman disks
(5mm diameter). The disks were put on an exponentially
growing plated culture with appropriate dilution to 1.0 ×
107 colony forming unit (CFUmL−1), which were then
incubated for 24h at 37
◦C. The inoculums used in growth
method were those where turbidity was equal to 0.5 McFar-
land Standard. The results were veriﬁed by measuring the
zones surrounding the disk. Ciproﬂoxacin and vancomycin
were used as positive controls and the halo >15mm was
considered the minimum value for positive antimicrobial
activity as it generally leads to a MIC near to that observed
for the newest antimicrobials current present on the market
(MIC = 1−40µgm L −1). Vancomycin and ciproﬂoxacin
presented halo 15 ± 2a n d2 3± 2mm, respectively in the
strains tested herein (P < .005).
2.2.2. MIC Assays. In order to determine the MIC of these
snake venoms, we tested them using the macro-dilution
brothmethod asdescribedelsewhere [13].Brieﬂy,after5hof
the bacterial growth, the culture was diluted to obtain 1.0 ×
105 CFUmL−1.Thesnakevenomwasaddedinordertoreach
a ﬁnal concentration from 0.5 µgmL −1 to 1024 µgmL −1
and incubated at 37
◦C for 24h. MIC was deﬁned as the
lowest concentration of venom or antibiotic current on
the market preventing visible bacterial growth compared to
the positive growth control (medium plus bacteria without
venom or antibiotic) that presented high turbidity, and
to the negative growth controls (medium alone, medium
Table 1: Antibacterial eﬀect of Viperidae venoms against Gram-
positive and Gram-negative drug-resistant clinical bacteria.
Strain Inhibition zone (mm)a
A. rhodostoma B. atrox B. jararaca L. muta
E. faecalis 16 ± 21 6 ±2 13 ± 11 ± 1
S. epidermidis 16 ± 11 8 ±2 00
S. aureus 13 ± 21 2 ± 1 16 ±1 2 ± 1
E. coli 11 ± 17 ± 15 ± 20
S. morcencens 8 ± 18 ± 27 ± 11 ± 1
P. mirabilis 7 ± 17 ± 17 ± 12 ± 1
P. aeruginosa 8 ± 28 ± 18 ± 11 ± 1
E. calcoacetic 9 ± 16 ± 26 ± 22 ± 1
A. calcoacetic 1 ± 22 ± 11 ± 11 ± 1
K. pneumoniae 9 ± 11 0 ± 11 0 ± 20
aThe values represent a venom inhibition zone in millimeters, after l8 h
incubation performed in triplicateassays(P<. 005).Signiﬁcant resultswere
considered the halo >15mm as vancomycin and ciproﬂoxacin presented
halo = 15–17 and 23–25mm, respectively.
plus venom or antibiotic and medium plus bacteria plus
eﬀective antibiotic) that presented no turbidity. All strains
were tested at least in duplicate in four separate experiments
andareferenceantibiotic(vancomycin)wasusedas standard
(MIC = 2µgmL −1).
2.3. Statistics. The statistical analyses were performed using
Microcal Origin 4.0 (MA, USA). The SD and signiﬁcance
(P) were determined by using one-way ANOVA from the
same graphicprogram.Resultswere consideredassigniﬁcant
when P < .005.
3.Results
3.1. Sensibility Assays of Venoms. Our experimental data
revealed that most of the venoms tested (A. rhodostoma,
B. atrox and B. jararaca) exhibited an antibacterial proﬁle
against some of the Gram-positive bacteria (Table 1). The
L. muta venom showed no antibacterial activity (Table 1)
even when it was obtained from diﬀerent Brazilian suppliers
(Instituto Butantan,Ezequiel Diasand Vital Brazil)(datanot
shown).
Agkistrodon rhodostoma was not signiﬁcantly eﬀective
against S. aureus and E. coli (Table 1). However, this venom
was able to signiﬁcantly inhibit E. faecalis and S. epidermidis
growth (halo = 16 and 16mm, resp.). Bothrops atrox venom
also showed an antibiotic proﬁle against E. faecalis and S.
epidermidis (halo = 16 and 18mm, resp.), diﬀerent from B.
jararaca venom, which acted only against S. aureus (halo =
16 mm) (Table 1). In addition, Bothrops venoms (B. atrox
and B. jararaca) inhibited growth of Staphylococcus sp. (S.
epidermidis and S. aureus,r e s p . ) .
3.2. MIC Assays of the Active Snake Venoms. The MIC assays
of the snake venoms that were active in the sensibility tests
(A. rhodostoma, B. atrox and B. jararaca) revealed that theirEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: MIC of Viperidae venoms presenting halo >15 mm.
Table 2: MIC of Viperidae venoms presenting halo >15mm.
Straina MIC (µgmL −1)
A. rhodostoma B. atrox B. jararaca
E. faecalis 4.5 4.5 —
S. epidermidis (A) 4.5 4.5 —
S. epidermidis (B) 4.5 4.5 —
S. aureus (A) — — 13
S. aureus (B) — — 13
a(A) and (B) on S. aureus and S. epidermidis refer to diﬀerent patients
strains.
level of antibiotic activity was comparable (MIC = 4.5–
13µgmL −1)( Table 2). Agkistrodon rhodostoma and B. atrox
were alsoanalogoustotheantibioticscurrentlyin useagainst
S. epidermidis, such as ampicillin, chloramphenicol, van-
comycin, oxacillin and penicillin G (MIC = 1–32µgmL −1)
(Figure 1).
4.Discussion
Our experimental data revealed that most of the venoms
tested (A. rhodostoma, B. atrox and B. jararaca) exhibited a
promising antibacterial activity against some of the Gram-
positive bacteria. Interestingly, despite of the presence of a
known phospholipase A2 [14], the L. muta venom showed
no antibacterial activity. Although literature described that
diﬀerent snake may present an individual pattern [5], L.
muta diﬀerent venom samples obtained from three diﬀer-
ent Brazilian suppliers(Governmental Institutes—Butantan,
Ezequiel Dias and Vital Brazil) were not able to aﬀect
the bacterial strains (data not shown). This negative result
reinforce the fact that the presence of enzymes in the snake
venoms do not guarantee the antibiotic proﬁle of these
m a t e r i a l sa st h eb a c t e r i ac e l lw a l lm a ya v o i do ra ﬀect the
actions of these proteins against them.
Diﬀerentlyfrom A. contortrix venom [12], A.rhodostoma
venom was able to signiﬁcantly inhibit E. faecalis and S.
epidermidis growth, which may suggest a speciﬁc mechanism
or molecule of A. rhodostoma on aﬀecting them.
Bothrops atrox venom also showed an antibiotic proﬁle
against E. faecalis and S. epidermidis,d i ﬀerent from B.
jararaca venom, which acted only against S. aureus. Recently,
the literature described l-amino acid oxidases (L-MAO)
isolated from B. pirajai [15]a n dB. alternatus venoms
[16] able to inhibit E. coli growth. Our result pointed to
the L-MAO isoforms presence in Bothrops sp. venoms as
preserved components similar to C-type lectin-like proteins
[17] .H o w e v e r ,a st h ea c t i v ep r o ﬁ l eo ft h e s ev e n o m ss w i t c h e d
to diﬀerent strains and not included E. coli,o u rr e s u l tm a y
also suggest that other antibacterial components may be
presentinthesevenomsresultedfromspeciesdiﬀerentiation.
In addition, Bothrops venoms (B. atrox and B. jararaca)
acted against diﬀerent Staphylococcus sp. (S. epidermidis and
S. aureus, respectively) once again suggesting that diﬀerent
molecules and/or targets are involved in these biological
activities. This hypothesis is reinforced by the presence of
other diﬀerent components found in snake venoms that
sometimes are involved in a similar biological activity as
RGD-peptides and some C-type lectin-like proteins from B.
jararaca venom that are both platelet aggregation inhibitors
[9].
Overall, our MIC assays revealed that the activity of
the venoms tested was comparable (MIC = 4.5–13µgmL −1)
among them. Agkistrodon rhodostoma and B. atrox were also
analogous to the antibiotics currently in use against S. epi-
dermidis, such as ampicillin, chloramphenicol, vancomycin,
oxacillin and penicillin G (MIC = 1−32µgmL −1). Presently,
S. epidermidis is an important nosocomial pathogen, dras-
tically aﬀecting immunocompromised patients and/or those
with indwelling devices, such as joint prostheses, prosthetic
heart valves and central venous catheters [18]. Therefore,
these venoms’ active proﬁle against this strain is of interest
for pursuing continuously an antibacterial molecule.
Proteomic technologies are improving and developing
rapidly [19]. An important goal of proteomic studies of
snake venoms is discovering molecules that may be used in
treatment of diseases or as drugs prototypes. Nevertheless,
these techniques may depend on the experimental data
generated so far to identify some of these unknown proteins
or peptides. Although snake venom peptides and proteins
have a limited direct therapeutical use due to their antigenic
and “digestible” structure, their usefulness as prototypes
has clear potential [9, 20]. Our data suggested that A.
rhodostoma, B. atrox and B. jararaca are feasible sources
for searching antimicrobial prototypes and designing new
antibiotics against drug-resistant clinical bacteria, and these
data may act as a start for investing on these venoms
proteomic study for prototypes searching.4 Evidence-Based Complementary and Alternative Medicine
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